HC Wainwright Has Positive Outlook of OLMA FY2026 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Olema Pharmaceuticals in a research note issued to investors on Friday, May 22nd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($2.24) for the year, up from their prior estimate of ($2.25). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.16) per share.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52).

A number of other brokerages have also recently issued reports on OLMA. Wall Street Zen raised Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. The Goldman Sachs Group cut their price objective on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Tuesday, April 21st. Citigroup lifted their price objective on Olema Pharmaceuticals from $60.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Finally, TD Cowen reissued a “buy” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $44.10.

Olema Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ OLMA opened at $13.55 on Wednesday. The stock has a market cap of $1.18 billion, a PE ratio of -6.71 and a beta of 2.05. The business has a fifty day moving average of $14.86 and a two-hundred day moving average of $20.77. Olema Pharmaceuticals has a 52-week low of $3.89 and a 52-week high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, insider Shawnte Mitchell sold 25,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total value of $606,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.56% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC increased its stake in shares of Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after buying an additional 1,232 shares in the last quarter. Torren Management LLC acquired a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at $88,000. Nisa Investment Advisors LLC increased its stake in shares of Olema Pharmaceuticals by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after buying an additional 477 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Olema Pharmaceuticals by 44.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after buying an additional 1,169 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.